James L. Gulley

Hematology | Oncology

10 Center Dr
Bethesda, MD 20892

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 290 publications

Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (2026) 101019].

Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (2026) 101019].

Journal: JTO clinical and research reports

Published: August 20, 2026

Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

Journal: Oncoimmunology

Published: August 06, 2026

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal: Journal for immunotherapy of cancer

Published: June 18, 2026

Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial.

Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial.

Journal: The Prostate

Published: June 01, 2026

Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.

Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.

Journal: Cancer immunology, immunotherapy : CII

Published: May 15, 2026

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.

Journal: Cancer medicine

Published: April 20, 2026

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.

Journal: Frontiers in immunology

Published: April 16, 2026

Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases.

Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases.

Journal: BMC cancer

Published: April 06, 2026

Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial.

Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial.

Journal: JCO oncology advances

Published: April 06, 2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: March 13, 2026

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Journal: Frontiers in immunology

Published: February 11, 2026

Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.

Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.

Journal: JTO clinical and research reports

Published: January 24, 2026

Showing 1-12 of 290

Last Updated: 09/26/2026